Hot Mid Cap Companies To Own For 2015

Hot Mid Cap Companies To Own For 2015: VIVUS Inc (VVUS)

VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company's drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug al so includes STENDRA, or avanafil.

Qsymia for the treatment of obesity was approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate.

The Company initially launched Qsymia for distribution to eligible patients through the home delivery networks of two certified pharmacies, CVS Pharmacy and Walgreens. Since then, it has expanded the distribution of Qsymia to include the home delivery networks of Express Scripts, Wal-Mart Pharmacy and, for its members only, Kaise! r Permanente. Clinical studies of topiramate, a component of Qsymia, in type 2 diabetics resul ted in a clinically reduction of hemoglobin A1c (HbA1c). The! Company's drug, STENDRA (avanafil), is an oral PDE5 inhibitor the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).

Advisors' Opinion:

• [By Leo Sun]

  With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk, low-growth biotech stocks that investors might consider avoiding: Inovio Pharmaceuticals (NASDAQ: INO  ) , VIVUS (NASDAQ: VVUS  ) , and Zogenix (NASDAQ: ZGNX  ) .

• [By James E. Brumley]

  Well, it was nowhere close to the way investors of VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) would have envisioned it happening two years ago, in terms of time or reason. The end result is all that matters though, and the end result for ARNA and VVUS finally looks like it could be a bullish one. Both stocks were jolted out of their losing streaks this week, and though there's always a chance they could slip back into downtrends again, both Arena and VIVUS are ready for a paradigm shift.

• [By John Udovich]

  Orexigen Therapeutics, Inc (NASDAQ: OREX), like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS), is a speculative small cap obesity drug stock that has the potential for coming up with the next big thing in the treatment of obesity that is increasingly a global problems. I should mention that we have recently added Orexigen Therapeutics to our SmallCap Network Elite Opportunity (SCN EO) portfolio as an extremely speculative biotech bet because its lead obesity drug candidate has the potential to be approved by September 11th of this year.

• [By Maria! Armental! var popups = dojo.query(".socialByline .popC"); popups.forEach]

  Vivus Inc.(VVUS) said it filed a patent-infringement lawsuit against Actavis (ACT) PLC alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-mid-cap-companies-to-own-for-2015-2.html